FAQs

VitaHydroKultur Investor FAQ

Welcome to the VitaHydroKultur (VHK) Investor FAQ. Below you’ll find comprehensive answers to the questions most commonly asked by prospective and current investors, including details on our technology, market opportunity, SEIS/EIS tax relief, and more.

1. Company & Business Model

Q1. What does VitaHydroKultur do?

A1. VHK operates a plant-powered bio-manufacturing platform using Total Controlled Environmental Agriculture (TCEA) to grow high-purity proteins and bioactives in vertical farms. We supply pharma-grade, cruelty-free ingredients—such as vegan collagen peptides—to the $65.7 billion cosmeceutical market.

Q2. How is VHK’s model different from traditional biotech?

A2. Instead of steel bioreactors, VHK uses modular vertical farms (IGS Scotland modules) and transient plant expression in Nicotiana benthamiana. This approach reduces capital and operating costs, accelerates time-to-market (weeks vs. months), and delivers consistent, non-GMO, endotoxin-free products.

Q3. What is VHK’s revenue strategy?

A3. We sell exclusively B2B to formulation labs, OEM manufacturers, and ingredient distributors. By embedding in existing cosmeceutical supply chains and offering free samples and pilot pricing, we accelerate adoption across multiple product lines.

2. Market Opportunity

Q1. How big is the cosmeceutical market?

A1. The global cosmeceutical market was $65.7 billion in 2024 and is projected to grow to $152.6 billion by 2034 (CAGR 8.8%). Demand for clean, vegan, clinically validated ingredients underpins this growth.

Q2. Why is there strong demand for plant-derived proteins and collagen?

A2. Consumers, regulators, and brands demand cruelty-free, sustainable, and transparent sourcing. Plant-based proteins eliminate animal testing and environmental concerns, command premium pricing, and comply with tightening regulations on animal-derived inputs.

3. Technology & Production

Q1. What is Total Controlled Environmental Horticulture (TCEH)?

A1. TCEH is a fully enclosed, climate-controlled vertical farming system. We manage every growth parameter—light spectrum, temperature, humidity, CO₂, and nutrients—via sensors and automation to deliver year-round, predictable protein expression

Q2. Why use Nicotiana benthamiana?

A2. This non-food, fast-growing plant excels at transient expression, producing high protein yields in 4–6 weeks without permanent genetic modification. Its low background metabolites simplify downstream purification.

Q3. How do you ensure purity and consistency?

A3. We use supercritical CO₂ extraction (solvent-free), closed-loop environmental controls, and batch-validated QA/QC protocols to guarantee pharma-grade purity, endotoxin-free, vegan-friendly output.

4. SEIS & EIS Tax Relief

Q1. What is SEIS and who qualifies?

A1. The Seed Enterprise Investment Scheme provides UK investors with 50% Income Tax relief on investments up to £100,000 per tax year. Qualifying investors must be UK taxpayers, not employees or >30% shareholders, and must hold shares for at least 3 years.

Q2. What SEIS reliefs apply to VHK?

A2. VHK’s seed round qualifies for SEIS Advance Assurance. Investors receive 50% Income Tax relief, 0% CGT on gains after 3 years, loss relief on at-risk capital, and 100% IHT relief after 2 years

Q3. What is EIS and who qualifies?

A3. The Enterprise Investment Scheme offers 30% Income Tax relief on investments up to £1 million per tax year (or £2 million for knowledge-intensive companies). Conditions mirror SEIS: UK taxpayer, non-employee, ≤30% shareholding, 3-year hold.

Q4. What EIS reliefs apply to VHK?

A4. VHK’s Series A+ qualifies for EIS Advance Assurance. Investors benefit from 30% Income Tax relief, CGT deferral & 0% on gains after 3 years, loss relief, and 100% IHT relief after 2 years.

5. Financial & Investment Highlights

Q1. How much is VHK raising and at what valuation?

A1. We seek £8 million at an £6 million pre-money valuation to fund R&D, facility commissioning, and commercial rollout in Sweden and the UK.

Q2. What are the financial projections?

A2. Forecast revenue grows from £0.7 million in 2027 to £17 million in 2031, with positive EBITDA from 2028 and net cash generation of £16.3 million by 2031. Gross margins expand from 57% to 83%.

Q3. What exit options exist?

A3. Potential liquidity routes include a public listing (targeted in 3–5 years), strategic acquisition by beauty or biotech players, private equity sale, or structured secondary transactions.

6. Risk Factors

Q1. What are the key risks?

A1. Execution risk (R&D, scale-up), regulatory approvals, IP protection, market adoption cycles, funding requirements, supply chain or talent shortages, and reputational/ethical compliance.

Q2. How does VHK mitigate risk?

A2. We hold SEIS/EIS Advance Assurance, partner with IGS Scotland, maintain dual-sourcing, embed sustainability and governance, and leverage founding team’s proven track record in vertical farming and biotech.

6. Risk Factors

Q1. What are the key risks?

A1. Execution risk (R&D, scale-up), regulatory approvals, IP protection, market adoption cycles, funding requirements, supply chain or talent shortages, and reputational/ethical compliance.

Q2. How does VHK mitigate risk?

7. Next Steps & Contact

If you’d like to receive our detailed Investor Pack or arrange a private briefing, please contact:

Daniel Stone
Head of Commercial & Investor Relations
admin@vhkgroup.co.uk
01892 25 15 25

Thank you for considering an investment in VitaHydroKultur—where plant science cultivates the future of cosmeceuticals.

Important Notice:

Investment opportunities in VitaHydroKultur are open exclusively to individuals who qualify as High Net Worth or Self-Certified Sophisticated Investors under the Financial Services and Markets Act 2000 (FSMA) and the Financial Promotion Order 2005. These categories of investors understand and accept the risks associated with early-stage investments and are capable of making informed decisions without the protections afforded to retail investors.